JB Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

JB Capital’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$4.9M	Sell	6,467 -1,881	-23%	-$1.42M	0.17%	74
2026 Q2	$5.21M	Buy	8,348 +1,697	+26%	+$1.16M	0.18%	67
2026 Q1	$5.14M	Buy	6,651 +62	+0.9%	+$47.5K	0.21%	51
2025 Q4	$5.09M	Sell	6,589 -173	-3%	-$117K	0.21%	49
2025 Q3	$3.8M	Sell	6,762 -142	-2%	-$80.3K	0.16%	69
2025 Q2	$3.62M	Buy	+6,904	New	+$3.85M	0.18%	66
2024 Q4	–	Sell	-332	Closed	-$349K	–	237
2024 Q3	$349K	Buy	332 +3	+0.9%	+$3.34K	0.02%	177
2024 Q2	$346K	Buy	329 +4	+1%	+$3.88K	0.02%	174
2024 Q1	$313K	Hold	325	–	–	0.02%	178
2023 Q4	$285K	Hold	325	–	–	0.02%	170
2023 Q3	$267K	Hold	325	–	–	0.02%	157
2023 Q2	$234K	Hold	325	–	–	0.02%	157
2023 Q1	$267K	Hold	325	–	–	0.02%	142
2022 Q4	$234K	Buy	+325	New	+$240K	0.02%	156

Other funds holding REGN

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Pinnacle Associates New York $8.92B AUM 43.91% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Vest Financial Mclean, Virginia $9.5B AUM 22.78% 1-Year Est. Return

GuoLine Advisory Singapore $1.16B AUM 31.35% 1-Year Est. Return

Atwood & Palmer Kansas City, Missouri $1.95B AUM 16% 1-Year Est. Return

Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $10.8B AUM 9.05% 1-Year Est. Return

LMCG Investments Boston, Massachusetts $1.86B AUM 40.01% 1-Year Est. Return

JB Capital's REGN Position: Q3 2026 in Review

JB Capital reduced its Regeneron Pharmaceuticals (REGN) stake by 23% in Q3 2026, selling an estimated $1.42M and leaving 6,467 shares worth $4.9M. The position accounts for 0.17% of the portfolio, ranked #74.

JB Capital first reported a position in REGN in Q4 2022 and has held it in 14 quarters since. The position peaked at $5.21M in Q2 2026. 352 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

JB Capital held 6,467 shares of Regeneron Pharmaceuticals worth $4.9M as of Q3 2026.
JB Capital sold 1,881 Regeneron Pharmaceuticals shares in Q3 2026, an estimated $1.42M.
Regeneron Pharmaceuticals made up 0.17% of JB Capital's portfolio in Q3 2026, its #74 holding.
JB Capital first reported a position in Regeneron Pharmaceuticals in Q4 2022 and has held it in 14 quarters since.
JB Capital's Regeneron Pharmaceuticals position peaked at $5.21M in Q2 2026.
352 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on JB Capital's 13F filing for Q3 2026, filed 19 Oct 2026.